Amarantus BioSciences, Inc. Appoints David A. Lowe, PhD to Board of Directors

SAN FRANCISCO, Nov. 6, 2013 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced the appointment of David A. Lowe, PhD to its Board of Directors. Dr. Lowe comes to Amarantus with over 35 years of experience in central nervous system (CNS) drug discovery and development within the biopharmaceutical industry, where he has served in senior roles with various major biopharmaceutical companies, as well as emerging biotechnology companies. Concurrently, Dr. Lowe's advisory firm, NeuroAssets Sarl, which has development expertise within the areas of neurology, endocrinology and ophthalmology, will be overseeing the translational development of MANF through first-in-man clinical studies, as well as advising on the development of the LymPro Test® blood diagnostic for Alzheimer's disease, PhenoGuard Protein Discovery Engine and potential additions to the Amarantus portfolio.

Help employers find you! Check out all the jobs and post your resume.